Unique Immunotherapy Combinations Come to the Forefront at SITC Meeting
January 27, 2021
In this trial, the previous observation of liver toxicity using CD137 agonism was not observed, suggesting a safe neoadjuvant dosing. Indeed, 30% of patients demonstrated pathologic responses. Further research may combine a way of overcoming immune checkpoint pathways with stimulatory agonists.